Abstract
When attacked by HIV, the immune system counteracts infection with elicitation of HIV-specific antibodies and cytotoxic T lymphocytes. In most cases however, these defenses are unable to resolve HIV infection, which progresses, if left untreated, ravaging the immune system and leading to AIDS and, eventually, to death. Nonetheless, there are additional components of the immune system, from both the innate and the adaptive components, that are associated with improved clinical status and, in some cases, even with protection from infection. Two distinct families of such factors have been studied in depth: chemokines and β-defensins. CCR5 chemokines, which are involved in adaptive immunity, are molecules produced by lymphocytes, and thus are likely to play a role in controlling HIV systemically. β- defensins are instead produced by epithelial cells, and thus are important in controlling infection at mucosal sites. Both of these families of molecules, therefore, are involved in crucial battlegrounds for fighting HIV infection. Here, we review the evidence that argues for their importance in AIDS pathogenesis and in preventive and therapeutic approaches to combat HIV infection. I wish to dedicate this work to my parents,Maria Teresa Ghiglieno and Giovanni Alfredo Garzino
Keywords: AIDS, HIV, CCR5, β-Defensins, RANTES, MIP-1α, MIP-β, MDC
Current Pharmaceutical Design
Title: Chemokines and Defensins as HIV Suppressive Factors: An Evolving Story
Volume: 13 Issue: 2
Author(s): Alfredo Garzino-Demo
Affiliation:
Keywords: AIDS, HIV, CCR5, β-Defensins, RANTES, MIP-1α, MIP-β, MDC
Abstract: When attacked by HIV, the immune system counteracts infection with elicitation of HIV-specific antibodies and cytotoxic T lymphocytes. In most cases however, these defenses are unable to resolve HIV infection, which progresses, if left untreated, ravaging the immune system and leading to AIDS and, eventually, to death. Nonetheless, there are additional components of the immune system, from both the innate and the adaptive components, that are associated with improved clinical status and, in some cases, even with protection from infection. Two distinct families of such factors have been studied in depth: chemokines and β-defensins. CCR5 chemokines, which are involved in adaptive immunity, are molecules produced by lymphocytes, and thus are likely to play a role in controlling HIV systemically. β- defensins are instead produced by epithelial cells, and thus are important in controlling infection at mucosal sites. Both of these families of molecules, therefore, are involved in crucial battlegrounds for fighting HIV infection. Here, we review the evidence that argues for their importance in AIDS pathogenesis and in preventive and therapeutic approaches to combat HIV infection. I wish to dedicate this work to my parents,Maria Teresa Ghiglieno and Giovanni Alfredo Garzino
Export Options
About this article
Cite this article as:
Garzino-Demo Alfredo, Chemokines and Defensins as HIV Suppressive Factors: An Evolving Story, Current Pharmaceutical Design 2007; 13 (2) . https://dx.doi.org/10.2174/138161207779313696
DOI https://dx.doi.org/10.2174/138161207779313696 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis
Current Drug Targets Molecular Pathophysiology of Cavernous Nerve Injury and Identification of Strategies for Nerve Function Recovery After Radical Prostatectomy
Current Drug Targets Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine The Evolution of Diagnosis and Management of Pediatric Biliary Tract Rhabdomyosarcoma
Current Pediatric Reviews Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Bone Marrow Reconstitution as a Relevant Model of Genetically Programmed Leukemia
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Clinical and Radiological Characteristics of SAPHO Syndrome
Current Rheumatology Reviews MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Current Pharmaceutical Design High-Throughput Techniques for Identifying microRNA Target Genes
Current Bioinformatics Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review
Current Medicinal Chemistry Antagonists of Growth Hormone-Releasing Hormone in Oncology
Combinatorial Chemistry & High Throughput Screening Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development
Current Cancer Drug Targets On the Origin of Epidermal Cancers
Current Molecular Medicine Editorial [Hot Topic: The Chemistry and Biology of Small Molecules Acting on Nucleic Acids (Guest Editors: P.B. Arimondo, T. Garestier, J.-L. Mergny Dedicated to the Memory of Professor Claude Helene)]
Current Medicinal Chemistry - Anti-Cancer Agents Recent Approaches to Improve the Antitumor Efficacy of Temozolomide
Current Medicinal Chemistry Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets